2014
Taxanes
Schwab CL, English DP, Roque DM, Santin AD. Taxanes. Anti-Cancer Drugs 2014, 25: 522-535. PMID: 24300913, PMCID: PMC3980024, DOI: 10.1097/cad.0000000000000057.Peer-Reviewed Original ResearchConceptsTaxane-based chemotherapyUse of taxanesGynecologic cancerRoute of treatmentRadiation sensitizing propertiesGynecologic malignanciesCervical cancerEffective therapyTreatment intervalAppropriate doseResponse rateNew treatmentsChemotherapeutic agentsTaxanesCancerSensitizing propertiesChemotherapyTreatmentActive agentsMalignancyDocetaxelOvarianTherapyAgentsDose
2007
The safety and utility of bone morphogenetic protein in anterior and posterior cervical-spine fusions
Lee R, White A, Grauer J. The safety and utility of bone morphogenetic protein in anterior and posterior cervical-spine fusions. Current Orthopaedic Practice 2007, 18: 270-275. DOI: 10.1097/bco.0b013e32810c00f6.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCervical spine surgeryRecombinant human bone morphogenetic proteinHuman bone morphogenetic proteinAnterior cervical spine surgeryAutologous bone graft harvestPosterior cervical spine fusionBone morphogenetic proteinSoft tissue edemaProspective clinical studyCervical spine fusionHigh fusion rateBone graft harvestMorphogenetic proteinsLocal complicationsBone graft alternativesCervical fusionCohort studyBony unionCervical spineClinical studiesSurgical techniqueLumbar spineAppropriate dosePurpose of ReviewInterestLocal swelling
2006
Bone Morphogenetic Protein for Pseudarthrosis Repair in Revision Cervical Spine Surgery
White A, Lee R, Grauer J. Bone Morphogenetic Protein for Pseudarthrosis Repair in Revision Cervical Spine Surgery. Seminars In Spine Surgery 2006, 18: 207-210. DOI: 10.1053/j.semss.2006.09.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCervical spine surgeryRevision cervical spine surgeryAnterior cervical spine surgeryRecombinant human bone morphogenetic proteinSpine surgeryProspective clinical studyOff-label useBone morphogenetic proteinCervical surgeryBone graft alternativesPseudarthrosis repairClinical studiesSurgical techniqueAppropriate doseAnimal modelsSurgeryGraft alternativesHuman bone morphogenetic proteinMorphogenetic proteinsPotent osteoinductive factorsRecent reportsOsteoinductive factorsComplicationsPseudarthrosesDose
2002
Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin.
Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, O’Reilly M, Kim HW, Baker C, Roach J, Ellis LM, Rashid A, Pluda J, Bucana C, Madden TL, Tran HT, Abbruzzese JL. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. Journal Of Clinical Oncology 2002, 20: 3804-14. PMID: 12228200, DOI: 10.1200/jco.2002.05.102.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAngiogenesis InhibitorsApoptosisBiomarkersCD3 ComplexCollagenDose-Response Relationship, DrugEndostatinsEndotheliumFemaleFluorodeoxyglucose F18HumansIn Situ Nick-End LabelingLasersMaleMiddle AgedNeoplasmsNeovascularization, PathologicPeptide FragmentsProspective StudiesRecombinant ProteinsTomography, Emission-ComputedConceptsTumor blood flowRh-EndoTumor cell apoptosisPositron emission tomographyBlood flowEndothelial cell apoptosisCell apoptosisClinical trialsAntiangiogenic therapyEndothelial cellsWeeks of therapyStart of therapyDose-finding clinical trialsRecombinant human endostatinHuman recombinant endostatinTreatment of cancerBiologic markersAntiangiogenic treatmentBiopsy specimensAppropriate dosePET scansBiopsy analysisHuman endostatinTherapyTumor tissue
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply